short presentation an all the oral as well as injectable hormonal contraceptives, inclusive of their mechanism of actions , adverse effects and advantages.
Role of Dydrogesterone in Threatened Abortion Dr Sharda Jain Lifecare Centre
*EXPERINCE SHARING By EXPERTS*
Dr Uma Rai(DGF *E*)
Dr Sangeetaa Gupta(DGF *E*)
Dr Neerja Varshney(DGF *E*)
Dr Surjeet Kapoor(DGF *E*)
Dr Rupam arora(DGF *E*)
Dr Meenakshi Ahuja(DGF *S* )
Dr.Harsha khullar(DGF *C* )
Dr Mamta mittal(DGF *N*)
Dr Leena Sreedhar(DGF *D*)
Dr.Dipti Nabh(DGF *E*)
Dr. Shama Batra(DGF *E*)
Dr Poonam Paul(DGF *SW*)
PAN DGF ( DELHI GYNAECOLOGIST FORUM) CME ON DYDROGESTERONE ON 3/2 /22
short presentation an all the oral as well as injectable hormonal contraceptives, inclusive of their mechanism of actions , adverse effects and advantages.
Role of Dydrogesterone in Threatened Abortion Dr Sharda Jain Lifecare Centre
*EXPERINCE SHARING By EXPERTS*
Dr Uma Rai(DGF *E*)
Dr Sangeetaa Gupta(DGF *E*)
Dr Neerja Varshney(DGF *E*)
Dr Surjeet Kapoor(DGF *E*)
Dr Rupam arora(DGF *E*)
Dr Meenakshi Ahuja(DGF *S* )
Dr.Harsha khullar(DGF *C* )
Dr Mamta mittal(DGF *N*)
Dr Leena Sreedhar(DGF *D*)
Dr.Dipti Nabh(DGF *E*)
Dr. Shama Batra(DGF *E*)
Dr Poonam Paul(DGF *SW*)
PAN DGF ( DELHI GYNAECOLOGIST FORUM) CME ON DYDROGESTERONE ON 3/2 /22
Role of progestogens in obstetrics and gynecologyAhmad Saber
The
different progestogens with their overlapping effects on estrogen, androgen, glucocorticoid,
and mineralocorticoid receptors are described in order to allow the clinician to make the most appropriate choice of progestogen.
PANEL DISCUSSION ON ENDOMETRIOSIS IN ADOLESCENTS (2018 )Lifecare Centre
PANEL DISCUSSION ON ENDOMETRIOSIS IN ADOLESCENTS (2018 ) MODERATOR
DR SHARDA JAIN
DR ILA GUPTA
DR DIPTI NABH
panelist
UMA RAI
RAJ BOKARIA
JYOTI AGARWAL
JYOTI BHASKER
RENU CHAWLA
DIPTI NABH
VANDANA GUPTA
Uterine Fibroids: Symptoms, Causes, Risk Factors & Treatment uterine fibroids aren't associated with an increased risk of uterine cancer and almost never develop into cancer
Role of progestogens in obstetrics and gynecologyAhmad Saber
The
different progestogens with their overlapping effects on estrogen, androgen, glucocorticoid,
and mineralocorticoid receptors are described in order to allow the clinician to make the most appropriate choice of progestogen.
PANEL DISCUSSION ON ENDOMETRIOSIS IN ADOLESCENTS (2018 )Lifecare Centre
PANEL DISCUSSION ON ENDOMETRIOSIS IN ADOLESCENTS (2018 ) MODERATOR
DR SHARDA JAIN
DR ILA GUPTA
DR DIPTI NABH
panelist
UMA RAI
RAJ BOKARIA
JYOTI AGARWAL
JYOTI BHASKER
RENU CHAWLA
DIPTI NABH
VANDANA GUPTA
Uterine Fibroids: Symptoms, Causes, Risk Factors & Treatment uterine fibroids aren't associated with an increased risk of uterine cancer and almost never develop into cancer
PCOD,How are they different ??Difficulties & Solutions made Easy , Dr. Sharda...Lifecare Centre
Tremendous advances and extensive human studies have uncovered the complexity and management of PCOD
Global prevalence -2.2% to 26% Roughly 1 in 15 women worldwide, (Lancet, 2007)
Evolution and current practices in emergency contraceptives BY DR ALKA MUKHER...alka mukherjee
ey facts
Emergency contraception (EC) can prevent up to over 95% of pregnancies when taken within 5 days after intercourse.
EC can be used in the following situations: unprotected intercourse, concerns about possible contraceptive failure, incorrect use of contraceptives, and sexual assault if without contraception coverage.
Methods of emergency contraception are the copper-bearing intrauterine devices (IUDs) and the emergency contraceptive pills (ECPs).
A copper-bearing IUD is the most effective form of emergency contraception available.
The emergency contraceptive pill regimens recommended by WHO are ulipristal acetate, levonorgestrel, or combined oral contraceptives (COCs) consisting of ethinyl estradiol plus levonorgestrel.
Hormonal contraception refers to birth control methods that act on the endocrine system. Almost all methods are composed of steroid hormones, although in India one selective estrogen receptor modulator is marketed as a contraceptive.
Hysterectomy vs levonorgestrel inter-uterine device
Hysterectomy was the most cost-effective treatment
Progesterone receptor modulators for the treatment of uterine fibroids
Progesterone receptor modulators (ulipristal acetate or mifepristone) were also identified as a potential new treatment by members of the Guideline Development group (GDG)
Pre-surgical medical treatment of uterine fibroids (progesterone receptor modulaters and gonadotrophin releasing hormone analogues)
The new evidence may favour ulipristal acetate over gonadotrophin releasing hormone analogue for some, but not all outcomes as a pre-treatment for uterine fibroids before myomectomy
Early Prediction, Proper Planning can lead to Prevention of Disastrous Progre...Indraneel Jadhav
Uterine Leiomyosarcoma (LMS), the rare, aggressive tumours carrying poor prognosis are mostly diagnosed incidentally at time of myomectomy/hysterectomy done for a presumed benign condition.
The incidence of LMS is1 in 10,000 general population. The incidence of leiomyosarcoma in uterine leiomyomas is between 0.13 to 0.29%
LMS generally arise from a solitary lesion and are a result of genetic instability (errors in p16, p53, Ki67) with aggressive biology and chemotherapy resistance.
LMS is characterized by early dissemination with an overall survival of less than 50% at 2 years.
The modern diagnosis of LMS is based on the work of Bell et al and includes a combination of features including
Diffuse moderate to severe cellular atypia
Mitotic count >10 mitotic figures/10 HPF
Coagulative tumor necrosis
INFERTILITY: Failure to conceive within one or more years of regular unprotected coitus.
PRIMARY INFERTILITY: Patients who have never conceived
SECONDARY INFERTILITY : Previous pregnancies but failure to conceive subsequently
Classification & conservative surgeries for prolapseIndraneel Jadhav
Stage 0
no prolapse
- Aa,Ba,Ap,Bp are all at -3
- C or D between tvl and < tvl -2
Stage I
most distal portion > 1cm above level of hymen
Stage II
<1cm proximal to or distal to the plane of hymen
Stage III
>1cm below the plane of the hymen
Stage IV
complete eversion, distal portion at least (tvl -2 cm)
Cervical incompetence is the inability for the cervix to retain an intra-uterine pregnancy till term as a result of structural and functional defects of the cervix
Cervical incompetence is the inability for the cervix to retain an intra-uterine pregnancy till term as a result of structural and functional defects of the cervix.
Vitamin D regulates estrogen biosynthesis through VDR’s
Direct regulation of the expression of the aromatase gene
Maintaining extracellular calcium homoeostasis
Vitamin D increases progesterone secretion by
Granulosa cell leutinisation – HOXA10 expression
Increased 3 β- HSD mRNA levels
Vitamin D increases placental sex steriod production
Regulates human chorionic expression
Secretion from human syncitiotrophoblasts (promoter- CYP19 )
Prediction of Gestational Diabetes Mellitus and Hypertensive Disorders in Pre...Indraneel Jadhav
Globally the burden of GDM and hypertension in pregnancy is increasing, and in India too it is 5-15%.
Although insulin resistance is a physiological phenomenon in normal pregnancy, in predisposed individuals this could lead to hyperinsulinemia with development of GDM, hypertensive disorders of pregnancy or both
Early recognition is the key to prevent feto-maternal complications in these medical disorders
Selective progesterone receptor modulators (SPRMs)
Stimulates growth :
Up regulating epidermal growth factor (EGF)
Down regulating tumour necrosis factor-alpha expression
Inhibits growth :
Downregulating insulin-like growth factor-1 (IGF-1) expression
NO EFFECT ON ESTRADIOL LEVELS
Mifepristone : 5 or 10 mg per day for 1 year
Ulipristal acetate: 5-10mg/day for 13 weeks
Pro apoptotic and anti-proliferative effects on fibroid cells
Indications and incidence of primary caesarean delivery in a multigravidaIndraneel Jadhav
Caesarean delivery - most commonly performed operations today
Worldwide increase in caesarean delivery rates
Primary caesarean delivery in multigravida means first caesarean done in patients who had delivered vaginally once or more
Previous normal delivery – a false sense of security
A genetic condition where affected people have male chromosomes and male gonads with complete or partial feminization of the external genitals
An inherited X-linked recessive disease with a mutation in the Androgen Receptor (AR) gene resulting in:
Functioning Y sex chromosome
Abnormality on X sex chromosome
Post Operative status in patients undergoing Total Laparoscopic HysterectomyIndraneel Jadhav
To determine the indications and complications of Total Laparoscopic Hysterectomy
Post procedure Hemoglobin fall, pain scoring and total hospital stay
Time interval for regain to work and associated delayed complications
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stockrebeccabio
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Telegram: bmksupplier
signal: +85264872720
threema: TUD4A6YC
You can contact me on Telegram or Threema
Communicate promptly and reply
Free of customs clearance, Double Clearance 100% pass delivery to USA, Canada, Spain, Germany, Netherland, Poland, Italy, Sweden, UK, Czech Republic, Australia, Mexico, Russia, Ukraine, Kazakhstan.Door to door service
Hot Selling Organic intermediates
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...VarunMahajani
Disruption of blood supply to lung alveoli due to blockage of one or more pulmonary blood vessels is called as Pulmonary thromboembolism. In this presentation we will discuss its causes, types and its management in depth.
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
These lecture slides, by Dr Sidra Arshad, offer a quick overview of physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar leads (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
2. PREGNANCY RATE (%)
DURING 1ST YEAR OF USE
Hatcher: Contraceptive Technology, 18th Ed
% of Women Experiencing
an Unintended Pregnancy
within the First Year of Use
% of Women
Continuing Use
at One Year
Method Typical Use Perfect
Use
No Method 85 85 42
Male Condom 15 2 53
Combined Pill and POP 8 0.3 68
Ortho Evra Patch 8 0.3 68
Vaginal Ring 8 0.3 68
DMPA 3 0.3 56
copper T IUD 0.8 0.6 78
Levonorgestrel IUS 0.1 0.1 81
Female Sterilization 0.5 0.5 100
Male Sterilization 0.15 0.10 100
5. 1st Clinical trials of COC were described by John Charles
Rock & Goodwin Pincus with approval of marketing in
USA in 1960.
Within 5 years it was used by 30 millions women all over
the world.
At the moment , COC is used by over
100 million women worldwide.
Failure rate
• 0.3%, perfect use
• 8% typical first-year use
• Effective, safe, rapidly reversible form of contraception
COMBINED ORAL
CONTRACEPTIVES ( COC )
6. COMBINED ORAL
CONTRACEPTIVES ( COC )
Commonly known as the “ Pill “
Widely Accepted & Most Effective Reversible method of
Fertility Control.
In 1951, India was the 1st country in world to introduce COC
in National programme of Family Planning.
15. PATTERNS OF PILL USE
• Monthly cycling 21/7
• Multiphasic Preparations
• Alters the dosage of both the estrogen and progestin
components periodically throughout the pill-taking schedule
• Reduction in pill-free intervals
• Using a 4-day pill-free interval is associated with greater
ovarian suppression.
• Extended cycle regimens (bicycling, tricycling)
• 42 – 84 active followed by 7 inactive pills
• Seasonale, Seasonique
• Continuous use
16. MONOPHASIC
Contains Estrogen & Progesterone in same amount in
Each pill .
Divided in 2 subgroups :
- Low dose pills : EE 30 – 35 microgm
- Very low dose pills : EE 15 – 25 microgm
Ovral –L; Mala-D; Mala-N LNG 0.15 mg /EE 30 mcg
Novelon Desogesterol 0.15 mg
/EE 30 mcg
Femilon Desogesterol 0.15 mg
/EE 20 mcg
Elogen Desogesterol 0.15 mg
/EE 20 mcg
Yasmin 3 mg DRSP/ EE 30 mcg
17. MULTIPHASIC
Contains low or variable amounts of Progesterone in
2 ( biphasic ) or 3 ( triphasic ) phases of cycles.
Biphasic :
constant EE – 35 microgm
progestogens : low in first 10 days
higher in next 11 days .
NOT POPULAR – MORE FAILURE RATE .
NOT AVAILABLE IN INDIA …
18. Triphasic : Triquilar –
- 0.03 EE +0.5mg l-norgestrel (1 - 6)
- 0.03 EE +0.75mg l-norgestrel (7-11)
- 0.03 EE +0.125mg l-norgestrel (12 - 21)
Total monthly intake – 0.68mg EE +1.92mg progesterone
• Adv. – high efficacy rates
- few side effects
- less break through bleeding
- does not affect s.cholesterol & LIPIDS
• Disadv. – high pregnancy rates if errors in pill intake .
MULTIPHASIC
19. GnRH triggers release of
FSH & LH
FSH & LH trigger ovulation
Estrogen & progesterone in
hormonal contraceptives
inhibit LH, FSH, and GnRH
secretion,
preventing ovulation
Progesterone:
•thickens cervical mucus to prevent
passage of sperm into the uterus
•changes uterine lining to inhibit implantation
MECHANISM OF ACTION:
20. MECHANISM OF ACTION
• Mostly a progestin effect
• Block LH surge, inhibiting ovulation. (breakthrough ovulation
rate 2-8% depending on EE dose)
• Thicken cervical mucus
• Inhibit capacitation of sperm
• Slow tubal motility
• Distrupt transport of fertilized ovum
• Endometrial changes (atrophy, underlying vascular function and
structure and alter the metalloprotein content)
• Estrogen (ethinyl estradiol or mestranol)
• Cycle control
• acts to inhibit follicular growth by decreasing FSH
21. SELECTION OF THE PATIENT
Detail history ( headache , migraine , etc…)
Thorough general examination
( Breast , blood pressure… )
Pelvic examination to exclude cervical pathology.
Cervical cytology
Rule out any other contraindications.
22. CHECKLIST FOR
PRESCRIBING COC…
Last menstrual period, rule out pregnancy
Less than 6 months postpartum & lactating?
Age, Cigarette smoking, h/o migraine
Known case of diabetes or hypertension
History of stroke, MI or thrombosis
h/o jaundice/ liver disease
h/o breast/ genital tract malignancies
h/o drug intake: Antitubercular, antiepileptic
23. ADMINISTRATION
New User :
- 1st day of Cycle .
- Daily 1 tab. Preferably at night for consecutive 21 days.
- Continued for 21 days and then 7 days break ( with iron
tablets ) .
- Next pack of Pill should be started on 8th day ,
IRRESPECTIVE OF BLEEDING ( same day of the week , pill
finished ).
- Simple Regimen of “ 3 WEEKS ON & 1 WEEK OFF “
- No break between packs.
Can start pill up to 5 days of bleeding with extra precaution
with condom for next 7 days.
24. PILL INITIATION
METHODS
• Quick-start
• Day of visit
• Reasonably sure not pregnant
• 7 days back-up
• Remind that menses may be delayed or irregular
• More successful at getting women started on the
pills.
• First-day start
• In regularly ovulating, normal menses
• Sunday start
• Back up needed for 7 days.
• Not usually recommended.
25. PILL INITIATION
METHODS
• Lactating Women –
Combined pills after 6 months
• Non Lactating Women –
Combined oral pills after 3 to 6 weeks or after menstruation
• 1st / 2nd Trimester abortion –
during first 7 days.
• Amenorrhea
At any time after excluding pregnancy +
barrier method for 7 days.
26. 1 missed –
Take 2 tablets next day .
2 or 3 missed –
Take 2 tablets on two consecutive days and continue the rest of
the pack.
+Another Contraceptive for 1 week.
MISSED
PILLS
27. SEASONALE
Available since 2003
150µg of LNG + 30µg of EE
Only Active Pills taken continuously for 84 days, then break
for 7 days.
Fewer periods (4 in a year)
Pearl index- 0.78
Breakthrough bleeding/ spotting – First few cycles
28. FOLLOW UP …
Examined after 3 months , then after
6 months and then yearly .
Ask for any symptoms…
Examination for breast , pelvis, BP & weight & cervical
cytology.
29. ADVANTAGES…
• Prevention of pregnancy
India - MMR 1per 57 i.e. 400 in 1,00,000
2/5th of these deaths can be prevented by use of OCs
• Cyclical Stabilisation
Great social advantage. Withdrawl
bleeding is predictable & postponed safely by taking
more low dose pills contineously .
30. • Cure of Menstrual Disorders
Dysmenorrhoea & Ovulation pain –
By inhibiting ovulation & production of PG .
Menorrhagia & Metrorrhagia –
Norgestrel High dose oral pills more useful.
Lessens PMT.
• Protection against Cancer
a) Endometrial cancer- Reduction by 50 %
effect persists for 15 yrs.
b) Ovarian Cancer – Reduction by 40 %
effect persists for 10 yrs.
c) Choriocarcinoma – Indirectly prevention by preventing
pregnancy.
ADVANTAGES…
31. • Protection against benign tumors
1) Fibrocystic and Fibroadenomatous disease
2) Ovarion Functional Cysts
1) Follicular Cyst – 50 %
2) Corpus Luteum Cyst – 80 %
3) Fibroid Uterus - Reduction by 30%
Low Dose OC’s reduce fibroid ( WHO 1996)
ADVANTAGES…
32. • Protection against diseases
1) Ectopic Pregnancy
2) PID
3) Anemia and Malnutrition
4) Endometriosis
5) Acne and Hirsutism
6) DUB
7) Osteoporosis
• Simplicity and Attractiveness
• No Affection on Future fertility ( 3 months )
ADVANTAGES…
33. EMERGENCY
CONTRACEPTION…
1) Yuzpe regimen –
0.1mg EE + 1 mg dl-Norgestrel
1st dose Within 72 Hrs of Contact
Repeated after 12 Hrs.
2) Ovral
1st dose 2 tablets within 72 hrs.
2nd dose 2 tablets after 12 hrs.
3) Overal – L
1ST dose 4 tablets within 72 hrs.
2nd dose 4 tablets after 12 hrs.
34. NEW ORAL CONTRACEPTION
• Newer progestogens –
Dienogest, Nomegestrel, Drospirenone
• Antiandrogenic activity with additional anti
mineralocorticoid activity of Drospirenone
• Significant reduction in the dosage
• Estradiol (E2) is used as estrogen instead of Ethinyl
Estradiol (EE)
Trials
• E2/Drospirenone & E2/Nomegestrol –
Monophasic & Triphasic formulation
• E2/Dienogest –
Quadriphasic formulation
35. • Estetrol (E4) –
• 18 times less potent than EE
• Fewer side effects
• Possibility of E4 protective against breast cancer is proposed
• Now classified as SERM
• Selective progesterone receptor blocker (SPRM)
block receptors in ovary, inhibit LH
a. Mifepristone : 5mg daily or 25mg weekly effective contraception
(Phase II Trial)
b. Ulipristal : daily pill
NEW ORAL CONTRACEPTION
36. Femcon Fe
(norethindrone 0.4mg & ethinyl estradiol 35mcg
& ferrous fumarate tablets)
Chewable birth control
Spearmint flavored
LoEstrin 24 Fe
(Norethindrone acetate 1mg & Ethinyl Estradiol 20mcg)
24 hormone days with 4 placebo days
NEWER PILLS
37. NEWER EC’S
Acts by delaying ovulation
Selective progesterone receptor modulator
a. Mifepristone 10mg
b. Ulipristal
COX 2 Inhibitors
a. Meloxicam - prevents rupture of dominant follicle , in
combination with LNG has better efficacy
b. Rofecoxib - delay in follicle rupture
38. MINOR SIDE EFFECTS…
1. Nausea, Vomiting and Lack of appetite
2. Break through bleeding (BTB)
3. Menorrhagia and irregular bleeding
4. Oligomenorrhoea and Amenorrhoea
5. Breast changes –
Heaviness and Tenderness
6. Vaginal Discharge –
Cervix -erosion, dysplasia causes leucorrhoea
7. Chloasma
8. Weight Gain
9. Psychosexual Trouble –
Depression, Loss of Libido
10. Others - Leg Cramps, Dimness of Vision
39. MAJOR SIDE EFFECTS…
• Cardiovascular Diseases
1) MI – Increased Risk in heavy smokers
2) Ischaemic Stroke - 1.5 times more
3) Haemorrhagic Stroke – double risk
4) Venous Thromboembolism – Risk increases with age,
recent surgery and thrombophilia
• Hypertension - In women more than 35 Yrs.
• Carcinogenecity
1) Breast Cancer
2) Cervical Cancer
45. MECHANISM OF ACTION
• Ovulation inhibition by decreased GnRH pulse
frequency.
• Suppression of midcycle LH and FSH surge
• Thickened and decreased cervical mucus
• Endometrial changes (atrophic endometrium)
46. MINI PILLS
Schedule
• 1st day of M.C. and a backup method for 7 days
• 6 wks after delivery – no backup method
• Missed Tablet – Backup method for 48 Hrs.
• Failure Rate - 3- 10 %
Lactating Women – 0.5 %
Advantages
Can be used above 16 yrs of age, Smokers & obesity
Best in DM, CVS Diseases & SLE
Disadvantages
Irregular Bleeding, Acne, Mastalgia, Amenorrhoea
49. • Dose Schedule
5 to 7 days of menstruation
Post- abortal – Immediate
Post- delivery – 6 Wks
• Technique : DMPA IM in arms
NET-EN in buttocks
( Needs warming )
INJECTABLE CONTRACEPTIVES
50. DEPO-SUBQ PROVERA 104
New formulation for subQ injection
30% lower dose (104 mg vs. 150 mg)
Rapid onset of action
Same effectiveness, same length of protection (>3 months)
Approved by USFDA (2005) and UK
Potential for home- and self-injection
Available for roll-out in 2011; Acceptability studies to begin in mid-2010
Uniject:
• Single dose, single package
• Prefilled, sterile, non-reusable
• Short needles for subQ injection (easier use by non-clinical
personnel/CHWs)
• Compact; easy to use and store
51. Mode of Action
• Inhibits ovulation
• Cervical mucus thickening
• Endometrial alteration
Eligibility criteria
Adolescents > 16 yrs of Age
Nulliparous
Obese / Thin
Smokers
6 Wks post delivery
Post Abortal
INJECTABLE CONTRACEPTIVES
53. Advantages
• Easy & Convinient to use
• Safe, no serious health effects
• Free from estrogen related
problems
• Reduces menstrual flow &
prevents anemia
• Suitable for lactating women
• Reduces risk- PID & vaginal
candidiasis
• Protects against endometrial
cancer for 8 years after
discontinuation
Disadvantages
• Irregular menstrual bleeding
• Weight gain
• Impaired glucose tolerance
• Affection of fertility- delay
• Risk of carcimona insitu &
invasive cervical carcinoma in
HIV
• Bone density changes
• Headache, weight gain,
dizziness, abdominal pain,
anxiety
54. HORMONE RELEASING IUD
Progestasert
Levonorgestrel IUD 20 – LNG 20
T Shaped
Hormonal capsules in the vertical rod.
Maintains high local level of progesterone and low
estrogen
55. Progesterone IUD
38 mg of progesterone
65 mcg of Progesterone / Day
Reduces Menstrual loss
Disadvantage
Costly
1 Yr. Life
Insertion may require LA / Sedation
HORMONE RELEASING IUD
56. MIRENA
40 – 60 mg of LNG on stem.
Release 20 mcg / Day
Life 5 Years
Failure Rate 0.1 to 0.4 %
Difficult Insertion due to greater thickness
Advantages –
Contraception
DUB
57. IMPLANTS
• Sub dermal drug delivery system
• ADV: - long acting , reversible, progesterone only
• TYPES OF IMPLANTS
1. Norplant – has 6 rods
2. Jadella & Norplant 2 – has 2 rods
3. Implanon – has 1 rod
UNIPLANT
• Single rod implant
• Nomegestrol 38 mg.
• Releases 100 microgm / day.
• For 1 year.
58. NORPLANT
• 6 Silastic rod – 3.4 mm x 2.4 mm
• 36 mg LNG
• Daily release 50 – 80 mcg for 1st yr.
30 – 35 mcg over next 5 yrs.
• Life 5 Yrs.
• Insertion –
Day 1 – 7 of M.C.
Immediately after abortion
6 Wks after delivery
59. TECHNIQUE
Arm / Forearm under the skin
Under L.A
Small incision made
6 rods inserted in fan shaped manner
Special trocar used for insertion
Effective within 24 Hrs.
Removal after 5 Yrs. under LA
60. Mechanism
• Suppression of Hypothalamic and pituitary hormones and prevents
ovulation
• Depresses endometrial growth
• Cervical Mucus thickening
Eligibility -
Women of all ages
Women who do not want pregnancy for several years
Disadvantages
1) Trained person required for insertion and removal
2) Irregular bleeding
3) Infection
4) Hematoma
5) Removal may be difficult
NORPLANT
61. JADELLE / NOR PLANT II
• 2 Solid Silastic rod
• 44 mm x 2 mm
• Inserted on medial aspect of upper arm
• 70 mg of LNG – Release 30 to 35 mcg daily
• Life 5 Years
Norplant
First month- 85µg
1year- 35µg
2year- 30µg
Jadelle
First month- 100µg
1year- 40µg
2year- 30µg
62. IMPLANON
• Long acting single rod subdermal implant
• Length – 4 cm ,2mm diameter
• DOSAGE: 68mg of crystalline etonorgestrel in ethylene
vinyl acetate copolymer
• DURATION : 3 years
63. ADVANTAGES :
Long acting sustainable contraceptive
Low systemic side effects
Can be used by lactating mothers
DISADVANTAGES :
Ectopic pregnancy- 1.3%
Local infection
EXPENSIVE
Has to insert & remove the capsules
IMPLANON
64. BIODEGRADABLE
• Cipronor ( Single Capsule) – IMPLANTS :
- LNG 26 mg
- begins to disappear after 12 months.
• INJECTABLE :
- Microsphere of 0.06 – 0.1 mm diameter with Norethindrone with or
without EE.
- Given over Gluteal muscle.
- Once injected , can’t be removed.
65. How they work :
• Hormones diffuse continuously from a reservoir within the
ring into the bloodstream absorbed through vaginal
epithelium
• Combined vaginal rings prevents ovulation, thicken the
cervical mucous & suppress the endometrial growth
Side effects :
leucorrhoea, vaginal discomfort, vaginitis, foreign body
sensation, coital problems, expulsion
CONTRACEPTIVE VAGINAL RINGS
66. Combined progestin & estrogen rings
Nestorone ring
(Nestorone 150-200mcg + EE 15-20mcg/day)
Effective 12 months (Phase III Trial)
Emergency contraception
Nuva ring
(Etonogetrel 120mcg + EE 15mcg/day)
Use for 3week & 1 ring-free week
CONTRACEPTIVE VAGINAL RINGS
67. Progesterone only rings (Progering)
Less effective
Preferred in lactating
Progesterone 10mg/day - Effective up to 4 months
Nestorone releasing ring - Effective up to 1 year
Ulipristal in vaginal ring – Trial on going
CONTRACEPTIVE VAGINAL RINGS
68. • Nuva ring releases 15µg ethinyl estradiol & 120µg
etonogestrel/day
• Circulating hormones reach target within 24hrs &
remains stable for 24hrs
• Requires insertion of new ring every 4weeks
• If ring is removed & not replaced within 3hrs-backup
contraception for 7days reqiured.
NUVA RING
Failure rate 0.3%
69. TRANSDERMAL CONTRACEPTION
How they work
• Patches release estrogen & progestin through the skin, prevents
ovulation, thickening the cervical mucus, suppressing endometrial
growth
• User replaces patch weekly for 3 weeks & 1 patch free week
3 layers :
a. Outer - polyester protective layer
b. Middle - medicated adhesive layer
c. Inner - polyester release liner
Ortho Evra
(EE 20mcg + Norelgestromin 150mcg / day)
Gestadone patch
(EE 18mcg + Gestadone 50mcg/ day)
70. TRANSDERMAL CONTRACEPTION
Spray on contraceptive (Nestorone)
Single daily progestin only spray-on*
Absorbed into the skin & diffuses into the blood stream
Inhibits ovulation
The Metered Dose Transdermal System - spray*
(*Phase 1 trial …..Australia )
Gel (Nestrone)
Single daily application
71. CENTCHROMAN ( SAHELI )
• Ormeloxifene .
• research product of CDRI , Lucknow
• Non steroidal , potent anti estrogenic , weak estrogenic.
• Prevent implantation of fertilized ovum .
• Orally 30 mg twice weekly for first 3 months then once a
week.
• Avoided in PCOD, liver , kidney disease.
73. MALE HORMONAL METHODS
New male pill
• Desogestrel + Testosterone
• Blocks the production of sperm - maintaining male
characteristics & libido
• Daily pill
• 100% effective and completely reversible in preliminary
clinical trials
• In clinical trials, all of the participants’ sperm counts dropped
to zero, which means that the male pill would be more
effective than the condom and even the female pill.
74. CatSper blocker
• Sperm rely on calcium ions in sperm tail for mobility &
fertilization
• Humans -ion-channel gene - CatSper.
• Blocking CatSper action - effective form of birth control
• Men or women could take this potential CatSper “blocker”
• It acts ”wherever sperm are present”
• Active only in fully developed sperm
MALE HORMONAL METHODS
75. GENDARUSSA
• First non hormonal male contraceptive pills.
• Developed by Indonesia.
• Active ingredient in Gendarussa disrupts an enzyme in
the sperm head, which weakens the ability of the sperm
to penetrate the ovum.
• The effect is short term and reversible – having no effect
on male hormones.
• Still under clinical trials…
76. The Male Patch (Adjudin)
Adjudin (2,4-dichlorobenzyl- 1H-indazole-3-carbohydrazide)
Non-hormonal male contraceptive
Acts by blocking maturation of sperm in the testes
No effect on testosterone production
• Normal spermatogenesis returned in 95% within 210 days
after the drug had been discontinued
• The oral dose effective for contraception - high : causing
side effects in muscles & liver
Patch or implant – Avoids 1st pass metabolism
MALE TRANSDERMAL PATCH
77. REFERENCES
• S Rowlands. New technologies in contraception. BJOG 2009; 116:230-239.
• Allen RH, Goldberg AB, Grimes DA. Expanding access to intrauterine contraception.
American Journal of Obstetrics and Gynecology 2009;201(5):456-61.
• Grimes DA, Lopez LM, Schulz KF, Immediate post-partum insertion of intrauterine devices
Review, published in The Cochrane Library2010, Issue 5.
• WHO, Family Planning A GLOBAL HANDBOOK FOR PROVIDERS Update 2011.
• “Guidelines for administration of emergency contraceptive pills by medical officers,”
Research Studies and Standard Division, Department of Family Welfare, Government of
India, June 2009.
• The essentials of Contraceptive Technology, a handbook for clinic staff, John Hopkins
Population Information Program, 2010.